Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17988092 | 0.85 | GLA (0.46) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL15818845 | 0.82 | GLA (0.50) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL11155988 | 0.82 | GLA (0.50) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| Acetic Acid SCHEMBL30331117 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2HTR4 | |
| SCHEMBL21472144 | 0.81 | GLA (0.48) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL21026033 | 0.80 | GLA (0.44) | GLAPOLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL25111010 | 0.80 | POLB (0.39) | POLBHTTSMN1; SMN2 | |
| SCHEMBL14609741 | 0.80 | SMN1; SMN2 (0.64) | POLBHTTKDM1ASMN1; SMN2 | |
| SCHEMBL6866270 | 0.80 | POLB (0.39) | POLBHTTSMN1; SMN2 | |
| SCHEMBL14609561 | 0.80 | HSD17B10 (0.45) | SMN1; SMN2GSK3BS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019101188-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES | BEIGENE, LTD. (GB) | 2019-05-31 | — | — | WO | disclosed |
| EP-3250552-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2016123387-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | GLA 1825/4885POLB 4088/4885HTT 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.